Should You Buy Bioventus Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Bioventus Inc. (BVS) is rated as a strong fundamental performer with a QOC score of 8.2/10. Trading at $13.00, our valuation engine evaluates whether the market price reflects the company's underlying earnings power.
The short answer: 6 of 10 CirclFi valuation models project upside for Bioventus Inc. (BVS) at $13.00 — the model consensus leans bullish, with a Quality Score of 8.2/10 and Value-Trap risk of 12/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Bioventus Inc. (BVS) in 2026?
What Is the Bull Case vs the Bear Case for Bioventus Inc. (BVS)?
| Bull case — $35.82 target (+175.6%) | Bear case — $4.35 target (-66.5%) |
|---|---|
| According to the CirclFi Quality of Company (QOC) framework, Bioventus Inc.'s score of 8.2/10 reflects durable competitive advantages that should sustain earnings power through market cycles. | According to the CirclFi Deep Alpha Valuation Engine, the EROIC Spread model sees the stock as overvalued with a fair value of $4.35 (-66.5%), suggesting that the market price embeds overly optimistic growth assumptions. |
| According to the CirclFi Deep Alpha Valuation Engine, the First Chicago model targets a fair value of $35.82 (+175.6%), anchoring the bull case with a methodology that evaluates base, bull, and bear scenarios simultaneously. | According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +242.1% spread between the most bullish and bearish models, signaling elevated analytical uncertainty. |
| Industry tailwind: therapeutic area leadership could provide meaningful support for Bioventus Inc.'s revenue and margin trajectory in the Medical Devices space. | Industry headwind: drug pricing legislation represents a meaningful risk for Bioventus Inc. and its Medical Devices peers. |
How Does BVS Compare to Its Medical Devices Peers?
Valuation data pages: MDNC · ITGR · USAQ · VMD · HAE · LIVN · MYO · LFWD · NVNO · IRMD · PODD
Which Other Stocks Score Like BVS on Quality?
Closest companies to BVS’s Quality of Company score of 8.2/10, across all industries.
- ERII — Energy Recovery, Inc. (QOC 8.2) · analysis
- NOBH — Nobility Homes, Inc. (QOC 8.2) · analysis
- PSA — Public Storage (QOC 8.2) · analysis
- BPOP — Popular, Inc. (QOC 8.2) · analysis
- WDAY — Workday, Inc. (QOC 8.2) · analysis
- ED — Consolidated Edison, Inc. (QOC 8.2) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Medical Devices Screens Does BVS Appear In?
So Is Bioventus Inc. (BVS) Worth Buying in 2026?
Our models don't have a clear verdict on Bioventus Inc.. At $13.00 vs. $13.64 median fair value, the median upside of +4.9% masks significant model disagreement (+242.1% spread). With quality at 8.2/10, this is a stock where the margin of error is wide and additional fundamental research is strongly recommended.
These are quantitative model outputs, not investment recommendations. Bioventus Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About BVS Stock?
Should I buy BVS stock right now?
Based on CirclFi's multi-model analysis, 6 of 10 models see upside for BVS at $13.00. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 8.2/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Bioventus Inc.?
Key risks include: wide model disagreement (723% spread), signaling high uncertainty; general market and sector-specific risks affecting Medical Devices companies. Always diversify and consult a financial advisor.
How does BVS compare to its competitors?
Among Medical Devices peers, BVS holds a Quality Score of 8.2/10. Comparable companies include MDNC (QOC 8.2), ITGR (QOC 8.2), USAQ (QOC 8.2). The relative ranking helps investors identify whether BVS offers better fundamental quality than alternatives in the same sector.
Is BVS a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. BVS's Quality Score of 8.2/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.
What price should I buy BVS at?
CirclFi does not provide target buy prices or price alerts. However, our 10 active models produce fair value estimates ranging from $4.35 to $35.82. At $13.00, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for BVS.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad